Study of Modifications Induced by Continued Direct Oral Anticoagulant Therapy during Atrial Fibrillation Ablation Procedures on Standard Hemostasis Parameters.
Marie MullerJulien GodetXavier DelabrancheLaurent SattlerDavid MillardHalim MarzakPaul Michel MertesAnnick SteibLelia GrunebaumLaurence JeselCharles Ambroise TacquardPublished in: Journal of clinical medicine (2023)
Our results raise the question of optimal management of intra-procedural heparin therapy and highlight the limitations of the ACT test, particularly in patients on apixaban.
Keyphrases
- atrial fibrillation
- venous thromboembolism
- end stage renal disease
- catheter ablation
- newly diagnosed
- chronic kidney disease
- ejection fraction
- direct oral anticoagulants
- peritoneal dialysis
- left atrial
- prognostic factors
- stem cells
- oral anticoagulants
- mesenchymal stem cells
- mitral valve
- growth factor
- percutaneous coronary intervention
- cell therapy